LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

LLY

770.92

+1.18%↑

JNJ

177.42

+0.4%↑

ABBV

221.42

+2.4%↑

UNH

340.3

-0.22%↓

AZN

77.91

+0.84%↑

Search

Alkermes PLC

Ouvert

SecteurSoins de santé

27.8 3.81

Résumé

Variation du prix de l'action

24h

Actuel

Min

26.69

Max

27.82

Chiffres clés

By Trading Economics

Revenu

65M

87M

Ventes

84M

391M

P/E

Moyenne du Secteur

12.812

35.664

BPA

0.291

Marge bénéficiaire

22.295

Employés

1,800

EBITDA

99M

113M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+46.99% upside

Dividendes

By Dow Jones

Prochains Résultats

23 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

66M

4.4B

Ouverture précédente

23.99

Clôture précédente

27.8

Sentiment de l'Actualité

By Acuity

50%

50%

185 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Alkermes PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 sept. 2025, 17:03 UTC

Principaux Mouvements du Marché

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sept. 2025, 16:49 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

GD Culture Shares Drop After Deal for Pallas Capital

16 sept. 2025, 16:11 UTC

Principaux Mouvements du Marché

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sept. 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sept. 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sept. 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sept. 2025, 21:10 UTC

Acquisitions, Fusions, Rachats

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sept. 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16 sept. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

16 sept. 2025, 20:25 UTC

Résultats

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sept. 2025, 20:24 UTC

Résultats

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sept. 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sept. 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sept. 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16 sept. 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sept. 2025, 18:40 UTC

Acquisitions, Fusions, Rachats

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sept. 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sept. 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sept. 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sept. 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sept. 2025, 16:53 UTC

Résultats

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sept. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

16 sept. 2025, 16:15 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Commodities Roundup: Market Talk

16 sept. 2025, 16:09 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Energy Roundup: Market Talk

16 sept. 2025, 16:09 UTC

Market Talk
Acquisitions, Fusions, Rachats

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sept. 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 sept. 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sept. 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sept. 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparaison

Variation de prix

Alkermes PLC prévision

Objectif de Prix

By TipRanks

46.99% hausse

Prévisions sur 12 Mois

Moyen 40.26 USD  46.99%

Haut 54 USD

Bas 26.13 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

13 ratings

8

Achat

5

Maintien

0

Vente

Score Technique

By Trading Central

27.95 / 30.91Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Strong Bullish Evidence

Sentiment

By Acuity

185 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat